These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25814695)

  • 1. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.
    Spelman T; Morris MD; Zang G; Rice T; Page K; Maher L; Lloyd A; Grebely J; Dore GJ; Kim AY; Shoukry NH; Hellard M; Bruneau J;
    J Epidemiol Community Health; 2015 Aug; 69(8):745-52. PubMed ID: 25814695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.
    Bruneau J; Zang G; Abrahamowicz M; Jutras-Aswad D; Daniel M; Roy E
    Clin Infect Dis; 2014 Mar; 58(6):755-61. PubMed ID: 24363333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.
    Aspinall EJ; Weir A; Sacks-Davis R; Spelman T; Grebely J; Higgs P; Hutchinson SJ; Hellard ME
    Int J Drug Policy; 2014 Jan; 25(1):179-82. PubMed ID: 24315504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA.
    Morris MD; Evans J; Montgomery M; Yu M; Briceno A; Page K; Hahn JA
    PLoS One; 2014; 9(10):e109282. PubMed ID: 25286346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.
    Kim NJ; Jin H; McFarland W; Raymond HF
    Int J Drug Policy; 2015 Dec; 26(12):1238-43. PubMed ID: 26365768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a novel scale for measuring interpersonal factors underlying injection drug using behaviours among injecting partnerships.
    Morris MD; Neilands TB; Andrew E; Maher L; Page KA; Hahn JA
    Int J Drug Policy; 2017 Oct; 48():54-62. PubMed ID: 28804051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
    Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
    BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.
    Corson S; Greenhalgh D; Taylor A; Palmateer N; Goldberg D; Hutchinson S
    Drug Alcohol Depend; 2013 Nov; 133(1):172-9. PubMed ID: 23791029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users.
    Burt RD; Thiede H; Hagan H
    Drug Alcohol Depend; 2009 Dec; 105(3):215-20. PubMed ID: 19720473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users.
    Hahn JA; Evans JL; Davidson PJ; Lum PJ; Page K
    Addiction; 2010 Jul; 105(7):1254-64. PubMed ID: 20491725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
    Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
    Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
    J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in HIV and HCV Risk Behaviors and Prevalent Infection Among People Who Inject Drugs in New York City, 2005-2012.
    Neaigus A; Reilly KH; Jenness SM; Hagan H; Wendel T; Gelpi-Acosta C; Marshall DM
    J Acquir Immune Defic Syndr; 2017 Jul; 75 Suppl 3(Suppl 3):S325-S332. PubMed ID: 28604434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.